Breaking 911: FDA revokes Emergency Use Authorization for Monoclonal Antibody treatment for Covid-19
(media.greatawakening.win)
You're viewing a single comment thread. View all comments, or full comment thread.
Comments (174)
sorted by:
Omgosh, from the article, how horrific. 🤮
"Even at this point of the interview, I was having concerns about the monoclonal antibodies based on the information I was hearing. But it was during the next portion of Dr. Madej’s answer that I became truly shocked.
“There’s a problem also with the human-mouse antibody cell line,” she continued. “It has a trade name called VelocImmune. So, I knew this, I recognized this from years ago when I had a very big practice here in Georgia. I took different cases, complicated, and of course I got cancer patients. Well, many of them were breast cancer patients that were put on a newer chemotherapy agent immunotherapy.
“And they use this same mouse-human line. It’s called VelocImmune, okay. So they took that line and they put this in this chemo-agent. At first, the people looked great. These women were doing wonderfully. ‘I feel good. My tumor shrank.’
“And then what happened within one to three years? Sometimes five but usually one to three years there was an allergic reaction, they called it, and a woman would come back loaded with cancer. All the organs looked like they had melted together. I couldn’t, nor could the radiologist, tell one organ from another. So, it was a fulminant, terrible reaction. This was a failure.
“They’re going to use the same mouse line on people right now. This is horrifying because, although people are only getting one or two of these doses, not many, this can’t be good.”
No, it definitely cannot be good."
VelocImmune is used in the production of REGEN-COV, not Sotrovimab. VelocImmune is a patented and trademarked Regeneron technology. REGEN-COV comes from mice cells; sotrovimab comes from hamster ovarian cells, apparently.
Sotrovimab leaves the body on average in 50 days. Not sure about REGEN-COV. The modification given to sotrovimab to make it last longer in the human body is of concern.
From what I can gather, people have developed the most issues from the mAbs used for MS and cancers themselves that are given more than once, over a longer period of time. They also are chimera/hybrid antibodies vs. “fully humanized.”
I still have concerns over the mAb treatment, and more research needs to be done. But a lot of that interview—or at least the article about it—seems to be from a doctor repeating big ticket panic items and not reporting on the actual drug facts. Dr. Madej hasn’t seen patients in a couple of years, so I am not sure how trustworthy her cancer diagnoses can be.